Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease

Inclusion Criteria: * Patients with age of 20-75 years old (inclusive) in Taiwan of both genders * Out-patients who had been diagnosed as non-erosive gastroesophageal reflux disease (NERD) * Patients with heartburn or regurgitation (either one) as main symptom at least 2 days a week and had been present for \> or = 1 month before screening * Patients with heartburn or regurgitation (either one) during the 7 days screening period, either with frequency for \> or = 4 days of mild symptom, or for \> or = 2 days of moderate to severe symptom * Patients have signed the informed consent form Exclusion Criteria: * Patients with erosive gastroesophageal reflux disease (GERD), Barrett's esophagus or esophageal stricture * Patients with active or healing gastroduodenal ulcer (except scars) * Patients with history of gastric, duodenal or esophageal surgery * Patients with malignant disease of any kind * Patients with intrahepatic stone, gallstone, gallbladder sludge, hepatic or pancreatic carcinoma as evidenced by abdominal ultrasonography * Patients with ischemic heart disease as evidenced by electrocardiogram * Female patients who are pregnant or nursing mother * Patients with a history of allergy to any of the study drugs or their related compounds * Patients with a history of alcohol or drug abuse * Patients with clinically significant liver disease (aspartate aminotransferase (AST), alanine aminotransferase (ALT)\>2 upper limits of normal) * Patients with clinically significant …